XML 63 R47.htm IDEA: XBRL DOCUMENT v3.5.0.1
License Agreement/Revenue Recognition (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
Apr. 30, 2014
Jun. 30, 2015
Ampio [Member]    
Revenue Recognition [Line Items]    
Deferred Revenue   $ 500,000
Proceeds from License Fees Received   418,000
Potential Milestone Payments Receivable   $ 3,200,000
Deferred Revenue Recognition Period   10 years
Percentage Of Royalty Rate Of Net Sales   25.00%
Vyrix Pharmaceuticals Inc [Member]    
Revenue Recognition [Line Items]    
Deferred Revenue $ 250,000  
Potential Milestone Payments Receivable $ 3,025,000  
Deferred Revenue Recognition Period 7 years  
Agreement Expiration Period 15 years